An observational study in Chronic Obstructive Pulmonary Disease, sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-29.
Sponsored by China-Japan Friendship Hospital · Observational
The national COPD screening program is in a cross-sectional manner at the baseline, planning to recruit a total of 800,000 participants from 160 districts or counties (5,000 for each site on average) from 31 provinces, autonomous regions or municipalities directly under the central government of China. The filtered COPD high-risk population and confirmed COPD patients will be managed and followed up according to the standardized clinical guidelines. The major aims of the program are to estimate the prevalences of COPD high-risk population and under- or miss- diagnosed COPD patients, and to manage the development and outcomes of the disease.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's planned enrollment of 800,000 is above the median of 157 across 929 observational studies indexed under Lung Diseases.
Browse Lung Diseases studies →China-Japan Friendship Hospital is the lead sponsor of 173 studies on the registry; 109 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults who are potentially under a high risk of suffering COPD with an age between 35 and 75 years are eligible to be recruited. The participants should be residents who were living in the survey area with more than six months in the past year.
Exclusion Criteria:
The local residents gain a COPD-SQ score \< 16.
Other: Comprehensive intervention and management Ⅰ
The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 either with or without bronchodilator administration.
Other: Comprehensive intervention and management Ⅱ
The participants have a COPD-SQ score ≥ 16 with a FEV1/FVC ≥ 0.70 after administration of bronchodilators.
Other: Comprehensive intervention and management Ⅲ
Mainly health advisory.
Health advisory and regular follow-ups.
Pharmaceutical and non-pharmaceutical (e.g. health advisory, rehabilitation, etc.) interventions according to standardized clinical guidelines, with regular follow-ups.
Lung function
The changes of lung function (e.g. FEV1, FVC, FEV1/FVC, etc.) (P.S.: it is hard to assume that the lung function would be improved or decling, especially for the pre- or early-COPD population)
Time frame: 2 years
Respiratory symptoms
The appearance frequencies of respiratory symptoms (e.g. cough, sputum, wheeze, dyspnea, etc.)
Time frame: 2 years
Exacerbations
The numbers of exacerbations (e.g. emergency department visit, hospital admission, etc.) that related to COPD
Time frame: 2 years
Plan to share: No — Data would be available on reasonable request from the principal investigator.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China-Japan Friendship Hospital